Core Viewpoint - Nanhua Biological (000504.SZ) significantly revised its 2024 annual performance forecast from a profit of 12.5 million to 15.5 million yuan to a loss of 19 million to 21 million yuan, triggering delisting risk warning conditions [1] Group 1: Performance Revision - The company’s 2024 net profit and net profit after deducting non-recurring gains and losses are both negative, with operating revenue below 300 million yuan, leading to a "*ST" designation for its stock [1] - The revision was attributed to return risks primarily related to the sales of the company's beauty products, as prior profit announcements were made before a comprehensive audit [5] Group 2: Business Transformation - Nanhua Biological has been transitioning towards beauty and anti-aging sectors, which are key areas of its recent business strategy, while previously being involved in real estate, media, biomedicine, and energy-saving industries [5] - The company has faced delisting risk warnings multiple times in the past due to consecutive years of losses, specifically in 2010, 2013, 2016, and 2019 [5] Group 3: Management and Control - The frequent changes in the company's business focus are linked to changes in its controlling shareholders, although the company asserts that there are no internal management issues or control deficiencies [5]

Group 1 - The company reported a significant decline in revenue for 2024, with total revenue of 237 million yuan, a year-on-year decrease of 33.55%, marking the third consecutive year of revenue decline [4][6] - The net profit attributable to shareholders was -89.94 million yuan, an improvement of 43.53% compared to the previous year's loss of 159 million yuan, indicating some progress in cost control and internal management [5][6] - Despite improvements in gross margin from 6.21% in 2023 to 11.44% in 2024, the absolute gross profit was only 27.1 million yuan, insufficient to cover operating costs due to the sharp decline in revenue [4][5] Group 2 - The company has faced continuous losses since 2021, with a cumulative loss exceeding 500 million yuan, highlighting ongoing concerns regarding profitability [5] - The net cash flow from operating activities was -70.45 million yuan, although this represented a 9.6% year-on-year improvement, it still indicates significant cash flow pressure [5] - In response to the risk of delisting, the company plans to implement measures such as revitalizing fixed assets, accelerating inventory turnover, and exploring new market opportunities, while also acquiring a 51% stake in a clean energy company to seek new growth points [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000584 证券简称：*ST工智（维权） 公告编号：2025-057 江苏哈工智能机器人股份有限公司 一、银行账户解除冻结基本情况 上海我耀机器人有限公司（以下简称"上海我耀"）与库卡柔性系统（上海）有限公司（以下简称"库卡 柔性"）采购合同纠纷一案，上海国际仲裁中心裁决不予支持库卡柔性的全部仲裁请求，相关部门从而 解除了因该案冻结上海我耀的部分银行账户；海宁市译联机器人制造有限公司（以下简称"译联机器 人"）与公司、海宁我耀合同纠纷一案，译联机器人向法院申请财产保全。后各方已达成经法院裁定有 效的调解协议，现本案已执行完毕，法院已解除海宁我耀之前持有的浙江哈工机器人有限公司的100% 股权（海宁我耀持有的浙江哈工100%股权于2024年10月变更登记至吴淳名下），且对公司部分银行账 户资金的冻结。以下是解除冻结的银行账户明细： ■ 二、本次公司银行账户新增冻结情况 因刘延中先生与公司、吉林市江机民科实业有限公司（以下简称"江机民科"）股权转让纠纷一案，公司 银行账户因诉讼相对方向法院申请强制执行而被冻结。以下是冻结的银行账户明细。 关于公司、子公 ...

Core Viewpoint - Qinghai Huading Industrial Co., Ltd. reported a net profit attributable to shareholders of the parent company of -89,935,284.53 yuan for the year 2024, leading to a proposal of no profit distribution or capital reserve transfer to share capital for the year [4][21]. Company Overview - Qinghai Huading primarily engages in the manufacturing of elevator components and gearboxes, with a focus on research, production, and sales. The company has faced challenges due to a weak real estate market and increased competition in the engineering machinery sector [5][11]. - The company completed the acquisition of 51% of Mangya Yuanxin Energy Co., Ltd., expanding its operations into natural gas, including LNG and CNG [5][12]. Financial Data and Indicators - The company reported a significant decline in net profit for 2024, with a total net loss of approximately 89.94 million yuan and accumulated undistributed profits of about -1.05 billion yuan [4][21]. - The company is subject to a delisting risk warning due to its financial performance, as it failed to meet the revenue threshold of 300 million yuan [14][60]. Major Events and Changes - The company’s subsidiaries have experienced revenue declines due to the downturn in the elevator industry, prompting efforts to develop new clients and business lines [11][12]. - The company has implemented measures to optimize production processes and reduce costs in response to market fluctuations [11][12]. Shareholder Information - The controlling shareholder, Qinghai Heavy Machine Tool Co., Ltd., holds a significant portion of voting rights, influencing the company's governance [7][8]. - Recent changes in control have occurred, with Wang Feng becoming the actual controller of the company, increasing his voting rights to 15.26% [9]. Risk Warning and Future Plans - The company is under a delisting risk warning due to its financial performance, with plans to enhance liquidity and reduce operational risks through asset management and market expansion [14][63]. - Strategies for 2025 include improving inventory turnover, exploring new markets, and enhancing internal controls to mitigate operational risks [63][64].

Core Viewpoint - The number of companies facing delisting due to stock prices falling below par value has significantly increased in the A-share market, with *ST Jiyao being a notable example [1][5]. Group 1: Company Specifics - *ST Jiyao (300108.SZ) has seen its stock price drop to 0.30 yuan, marking the 18th consecutive trading day below 1 yuan, which may lead to early delisting [2][4]. - The company is primarily engaged in the pharmaceutical industry, including production, wholesale, retail, and healthcare services [4]. - Financially, *ST Jiyao has reported continuous losses, projecting a net loss of 500 million to 850 million yuan for 2024, with an expected negative net asset value of -1.18 billion to -830 million yuan [4]. Group 2: Market Trends - Recent statistics indicate a rise in A-share companies that have received notices for potential delisting due to stock prices consistently falling below 1 yuan, including *ST Xulan, *ST Jiayu, *ST Dongfang, and *ST Furun [5]. - *ST Dongfang received a notice on April 14, 2025, regarding the termination of its stock listing after 20 consecutive trading days below 1 yuan [5]. - *ST Furun has faced both par value and market value delisting risks, having received a notice on April 10, 2025, for similar reasons [5]. Group 3: Operational Challenges - Companies like *ST Jiayu are under significant operational pressure, with a reported 59.94% decline in sales revenue to 482 million yuan, and a net loss of 356 million yuan for 2024 [6]. - The focus for many of these companies is on risk management and debt resolution, with efforts to stabilize operations amid financial difficulties [6].

4月21日晚间，岩石股份（600696）(600696，又称上海贵酒)发布的2024年年报显示，公司当年实现营 业收入约为2.85亿元，净利润约为-2.17亿元。 由此，岩石股份将被实施退市风险警示，将"披星戴帽"。岩石股份表示，公司股票4月22日停牌一天， 并于4月23日起实施退市风险警示，其股票简称由"岩石股份"变更为"*ST岩石"。 审计机构中兴财光华会计师事务所(特殊普通合伙)对上海贵酒2024年度财务报表进行审计，并出具了保 留意见审计报告。值得注意的是，这已是岩石股份连续第三年被审计机构出具"保留意见"。去年营收同 比下滑超8成经销商减少超3693家 财报显示，岩石股份2024年营业收入为2.85亿元，同比下降82.54%；净利润为亏损2.17亿元，而2023年 净利润为8707万元；经营活动产生的现金流量净额-7546.18万元。 公司在年报中称，2024年，受多方面因素影响，公司资金承压，市场投放减少。叠加公司实际控制人被 公安机关采取强制措施和控股股东及其一致行动人所持公司股票被司法冻结等一系列事件影响，经销商 对于补货、备货持更加审慎观望态度，导致公司营业收入与上年同期相比大幅减少，且经营 ...

Core Viewpoint - The Shenzhen Stock Exchange has announced the termination of the listing of Hainan Puli Pharmaceutical Co., Ltd. due to significant financial fraud, which involved false reporting of profits totaling 669 million yuan over two years, constituting 73.83% of the reported profits for those years [1][3][5]. Financial Fraud Details - Puli Pharmaceutical falsely recognized sales revenue and profits by fabricating sales of finished and raw pharmaceutical products, leading to inflated revenues of 436 million yuan in 2021 and 456 million yuan in 2022, which represented 28.90% and 25.23% of the reported revenues for those years, respectively [4][5]. - The company also misreported revenues from trading activities, resulting in additional inflated revenues of 78 million yuan in 2021 and 59 million yuan in 2022, accounting for 5.17% and 3.28% of the reported revenues [4][5]. Regulatory Actions - Following the issuance of the administrative penalty decision by the China Securities Regulatory Commission (CSRC), the Shenzhen Stock Exchange initiated the process for terminating the listing of Puli Pharmaceutical's stock and convertible bonds [7][8]. - The stock was suspended from trading on March 24, 2025, with a closing price of 2.49 yuan per share and a total market value of 1.398 billion yuan [8]. Company Background - Puli Pharmaceutical, established in 1992, specializes in drug research, production, and sales, and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in 2017 [8]. Ongoing Investigations and Consequences - The CSRC has indicated that administrative penalties and forced delisting are not the end of the matter, as they will pursue comprehensive accountability for those involved in the financial fraud [12]. - The CSRC has also emphasized the importance of protecting investors' rights and will assist affected investors through various legal means [12].

星标 ★ IPO日报 精彩文章第一时间推送 4月18日晚间，海南普利制药股份有限公司（300630.SZ，以下简称"*ST普利"或"普利制药"）发布公告，公司于2025年4月18日收到深交 所《关于海南普利制药股份有限公司股票及可转换公司债券终止上市的决定》。深圳证券交易所决定终止公司股票及可转债上市。 公司股票及可转债进入退市整理期的起始日为2025年4月28日，退市整理期为十五个交易日，预计最后交易日期为2025年5月21日。 制图：佘诗婕 虚增利润近7亿 今年3月，上市公司发布公告称，收到证监会行政处罚决定书。 2021年至2022年，普利制药通过虚构成品药和原料药销售业务的方式，虚假确认药品销售收入和利润。 其中，2021年多计营业收入 436004495.01元，占当年披露营业收入的28.90%，对应营业成本128197101.98元，多计利润总额290175562.61元，占当年披露利润 总额的 62.06% ；2022年多计营业收入455776233.78元，占当年披露营业收入的25.23%，对应营业成本69013203.17元，多计利润总 额 379066467.07元，占当年披露利润总额的8 ...

以下文章来源于征探财经 ，作者征探君 征探财经 . 资本市场的征探君。把征探财经设置为星标，不会错过每篇文章哦～～ 作者丨五仁 来源丨征探财经 4月16日，洪九果品（6689.HK）发布公告称，公司董事长邓洪九，董事彭何、江宗英、杨俊文、谭波及监事会主席余利霞等，目前均已被采取不 同刑事强制措施，原因与重庆市两江新区公安分局就涉嫌骗取贷款及/或虚开增值税专用发票之事项进行的立案侦查相关。 同时，该事件导致自2025年1月6日起公司主要办公场所之一重庆市渝北区东湖南路3号中铁峰汇B座22层被公安机关限制人员出入，公司无法正常 办公。 2024年3月，洪九果品因延迟刊发2023年年报，在港交所停牌，至今已超过一年。目前，其2023年年报、2024年中报、2024年年报均未公告。 有着水果第一股之称的洪九果品，似乎难以度过此次危机了。 01 财报连续"难产" 2002年，邓洪九与妻子江宗英在重庆成立了洪九果品，从事生意。2022年9月，洪九果品在港交所上市，市值一度逼近200亿港元，成为水果第一 股。而今其市值仅27.95亿港元。 招股书显示，按2021年的销售收入计，洪九果品是中国最大的榴莲分销商，以及火龙果、山 ...

将投中网设为"星标⭐"，第一时间收获最新推送 大胆资本和耐心资本的本质是社会信用，资本市场是社会信用的更高等级的形式。 整理丨 陶辉东 来源丨 投中网 中国创投的退出有多难？ 基石资本董事长张维用他们对全亿健康的控股投资举例，生动展现了这一点。从 2016 年开始，基石资本通过五年整合，让全亿健康成为一家年销售额 达 60 亿元、门店逾 2000 家的连锁药房企业。但一算账发现，如果要想实现 A 股上市并减持退出，至少需要 17 年的时间。最终，基石资本选择把 它卖给了某国际知名私募巨头。"他们的基金周期是 12 年，而我的基金周期是' 5+2 '。" 中国创投面临的是"上市难"与"减持难"的双重难题。这样的现状，对于耐心资本和大胆资本的形成非常不利。张维指出，对上市和减持的严防死守，削 弱了创业的财富效应，因为投资的本质是为了增值，如果不能增值为什么投资？创业者如果不能卖股票又为什么要创业呢？ 历史上的股权分置改革，释放了大量的流通股，股市迎来一个牛市。张维认为，核心是实行真正的注册制，同时实行严格的退市制度，进一步打击造假 和违规信批，从而使资本市场实现动态平衡。 更进一步，张维认为大胆资本和耐心资本的本 ...